Milwaukee, WINCT05301101Now EnrollingIRB Ready

Solid Tumor Clinical Trial in Milwaukee, WI

Access cutting-edge solid tumor treatment through this clinical trial at a research site in Milwaukee. Study-provided care at no cost to qualified participants.

Sponsored by Medical College of Wisconsin

Quick Self-Assessment

See if you qualify for this Milwaukee location

Preparing your pre-screening questions…

Expert Care in Milwaukee

Access solid tumor specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related solid tumor treatment provided free

Apply for This Milwaukee Location

Check if you qualify for this solid tumor clinical trial in Milwaukee, WI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Milwaukee

    Convenient for WI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Milwaukee site if eligible
  4. 4Begin participation

About This Solid Tumor Study in Milwaukee

This trial applies a uniform approach to re-irradiation for planning and diagnostic image fusion, dose summation, dose calculations, and follow up for tumor control and detailed toxicity analysis of serial Organs At Risk (OARs). Serial organs include named arteries and nerves, spinal cord, and gastrointestinal tract.

Sponsor: Medical College of Wisconsin

Who Can Participate

Inclusion Criteria

Provision of signed informed consent
Patients ≥18 years of age receiving definitive or postoperative high dose radiation to volume that includes overlap with previously irradiated OAR(s).
Prior radiation dosimetry must be available.
Participants must have stage I-IV biopsy proven solid malignancy (histologic proof or unequivocal cytologic proof solid tumor malignancy from either the primary or any metastatic site). Documentation of pathology reports are required. Local review of pathology or cytology is at the discretion of the multidisciplinary team.
Histologic confirmation of target lesion recurrence is recommended.
Documentation of consensus for recommendation of reirradiation by multidisciplinary team and location of target lesion or postoperative site to be treated.
Documentation of whether or not concurrent cancer therapy drugs are recommended and rationale.
Documentation of rationale for not obtaining tissue confirmation of the target lesion, if applicable.
Baseline target lesion imaging with CT, positron emission tomography (PET) /CT, or MRI is required within six weeks of trial enrollment. CT or MRI simulation scans may be used for baseline imaging.
Patients who have had disease resected in a previously irradiated field and are at high pathological and clinical risk for recurrence as defined by the treating Radiation Oncologist and multidisciplinary team, are eligible for study.
Measurable disease is not required for patients being treated postoperatively.
Baseline labs are per standard practice. Values will be dependent on the OARs being treated. (Per standard practice, radiation therapy volumes to OARs are modified to accommodate compromised renal, liver, pulmonary or other OAR function). Recommended labs and values include:
Aspartate transaminase (AST) and alanine transaminase (ALT) \< 2.5 x upper limit of normal (ULN) or \< 5 x ULN with metastatic liver disease.
Total bilirubin \< 1.5 x ULN
Absolute neutrophil count (ANC) \> 500 cells/mm\^3
Platelets \> 50,000 cells/mm\^3
Creatinine \< 1.5 x ULN or Creatinine clearance \> 45 mL/min if creatinine is \> 1.5 x ULN (calculated Creatinine Clearance (CrCl) based on Cockcroft-Gault equation)
Eastern Cooperative Oncology Group (ECOG) Performance Score 0-2.
Patients must have resolution of acute toxic effect(s) of most recent cancer therapy to Grade 1 or 2.
Life expectancy of at least 6 months.
Female patients of childbearing potential must have negative urine or serum pregnancy test within 7 days prior to start of re-irradiation.
Ability to complete the self-reported questionnaires (translations will be made available if the patient's primary language is not English).
Concurrent participation on pharmaceutical, investigator-initiated, National Clinical Trials Network (NCTN), or other multisite clinical trials that include re-irradiation is allowed.

Exclusion Criteria

Patients receiving low dose radiation for symptom management only.
Patients with evidence of severe or uncontrolled systemic conditions.
Life expectancy of less than 6 months.
ECOG Performance status ≥ 3.
Women of childbearing potential who are known to be pregnant or are unwilling to use an acceptable method of contraception from the time of informed consent until completion of the course of radiotherapy

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Milwaukee?

Yes, this clinical trial (NCT05301101) has an active research site in Milwaukee, WI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumor Treatment Options in Milwaukee, WI

If you're searching for solid tumor treatment options in Milwaukee, WI, this clinical trial (NCT05301101) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Milwaukee research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumor clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Milwaukee, WI

See all advanced solid tumors clinical trials recruiting in Milwaukee — not just this study.

Browse Advanced Solid Tumors Trials in Milwaukee →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAll Conditions →

Ready to Join in Milwaukee?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Milwaukee, WI